TRBV22-1

Across TCGA pan-cancer cohorts, TRBV22-1 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated TRBV22-1 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRBV22-1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRBV22-1 expression acts as an unfavorable survival marker, although some lineages such as LAML and ESCA show a favorable association.

STAD, MESO, and LIHC are the cancer types where TRBV22-1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	IV	0.068	0.480	<.001	108	view →
MESO	OS	Tertile	III,IV	0.077	0.580	<.001	90	view →
LIHC	DFS	Tertile	All	0.045	0.553	<.001	45	view →
UCEC	DFS	Tertile	All	0.603	0.845	<.001	36	view →
LAML	DFS	Median	All	0.646	0.482	.015	34	view →
KIRC	DFS	Tertile	All	0.229	0.634	.011	30	view →
ESCA	DFS	Tertile	All	0.858	0.339	.033	30	view →
OV	OS	Tertile	All	0.886	0.823	.020	28	view →
BRCA	DFS	Tertile	All	0.773	0.905	.017	24	view →
COAD	OS	Tertile	All	0.493	0.873	.011	18	view →
READ	OS	Tertile	II,III,IV	0.287	0.829	.008	18	view →
LGG	DFS	Tertile	All	0.289	0.735	<.001	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

TRBV22-1–STAD (DFS)

Open the STAD breakdown →